Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.
You may also be interested in...
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
Deal Watch: Bristol Places Early Wager On Padlock's Autoimmune Potential
Regeneron and Bayer look to build on their past success collaborating in ophthalmology by partnering to develop an Eylea successor. Sun Pharma builds its portfolio with 13 products from Novartis.
Regeneron/Bayer Partnership Seeks To Build Upon Eylea's Success
Latest ophthalmologic collaboration between the partners seeks to create an Eylea successor by combining aflibercept with an Ang2 antibody.